

May 28, 2025



NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

The company expands precision oncology portfolio with new Palettra spatial proteomics platform

FORT MYERS, Fla.--(BUSINESS WIRE)-- **NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO)**, a leading provider of oncology diagnostic solutions that enable precision medicine, will debut its PanTracer™ Family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30–June 3, 2025. The company will also unveil Palettra™, its new AI-driven spatial proteomics platform designed to provide clear, actionable insights from tissue samples.

"The debut of the PanTracer Family and Palettra represents a significant milestone for NeoGenomics and a step forward in precision oncology," said Warren Stone, President & Chief Operating Officer at NeoGenomics. "By equipping clinicians and drug developers with the tools to make faster, more informed decisions, we're helping transform cancer care and accelerate innovation across the continuum of oncology diagnostics."

The [PanTracer Family](#) is designed to provide oncologists with timely and actionable genomic insights, supporting treatment decisions for patients with advanced-stage solid tumors. The portfolio includes PanTracer™ Tissue for comprehensive profiling from Formalin-Fixed, Paraffin-Embedded tissue, PanTracer™ LBx for liquid biopsy applications where tissue is unavailable or insufficient, and PanTracer™ Tissue + HRD, which adds homologous recombination deficiency testing to enhance therapy stratification. These assays can be used independently or as complementary tools, allowing clinicians to tailor their approach based on patient-specific needs. It also ensures fast, reliable access to the data needed to explore targeted therapies or clinical trials.

[Palettra](#) is an AI-powered spatial proteomics platform that transforms precious tissue into high-plex, image-based insights. Built for translational research teams, Palettra combines deep pathology expertise with integrated multimodal analysis to decode the tumor microenvironment and validate mechanisms of action. Palettra provides a scalable, high-touch solution that enables both large biopharma and emerging biotech companies to make more informed therapeutic decisions—helping teams see the biology more clearly, faster, and with confidence.

NeoGenomics will showcase both solutions at Booth #11093 at the meeting, including an interactive experience, “Hey Neo,” to help attendees explore how PanTracer supports therapy selection in real-world settings.

The company will also present a scientific poster at ASCO 2025, along with two abstracts published online. These achievements reinforce the company's role as a research-driven partner to the biopharma community, supporting oncology drug development and clinical trials through cutting-edge diagnostics and scientific insight. The abstracts include:

- **Abstract #5568/Poster Board #466 (poster presentation):** [Real-world analysis of folate receptor alpha \(FR \$\alpha\$; FOLR1\) expression in pan-tumor samples from over 6000 patients in the US](#)
- **Abstract #e15180 (online publication):** [The cancer fusionome and overexpressed druggable oncogenic signals in K-RAS wild-type pancreatic cancer](#)
- **Abstract #e15047 (online publication):** [Analytical validation and clinical performance of a plasma-based CGP assay, NEO | PanTracer LBx](#)

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including

those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250528255379/en/>

Investor Contact

Kendra Sweeney

kendra.sweeney@neogenomics.com

Media Contact

Andrea Sampson

asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.